Brokerages Set NeuroPace, Inc. (NASDAQ:NPCE) PT at $18.67

NeuroPace, Inc. (NASDAQ:NPCE) has received a consensus recommendation of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $18.6667.

A number of analysts recently weighed in on NPCE shares. UBS Group reaffirmed a “buy” rating on shares of NeuroPace in a research report on Wednesday, January 14th. Leerink Partners reaffirmed an “outperform” rating and issued a $19.00 target price on shares of NeuroPace in a research report on Wednesday, November 5th. JPMorgan Chase & Co. increased their target price on NeuroPace from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. Cantor Fitzgerald reissued an “overweight” rating and set a $16.00 price target on shares of NeuroPace in a research report on Wednesday, November 5th. Finally, Wells Fargo & Company upped their price target on NeuroPace from $15.00 to $16.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th.

Institutional Investors Weigh In On NeuroPace

Large investors have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. lifted its holdings in NeuroPace by 83.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,455 shares of the company’s stock worth $27,000 after buying an additional 1,118 shares in the last quarter. Legal & General Group Plc grew its stake in shares of NeuroPace by 86.0% during the second quarter. Legal & General Group Plc now owns 2,679 shares of the company’s stock valued at $30,000 after acquiring an additional 1,239 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of NeuroPace during the second quarter worth about $35,000. Quarry LP lifted its stake in shares of NeuroPace by 94.9% in the third quarter. Quarry LP now owns 3,845 shares of the company’s stock worth $40,000 after acquiring an additional 1,872 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey boosted its holdings in NeuroPace by 72.0% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 6,371 shares of the company’s stock valued at $71,000 after purchasing an additional 2,668 shares during the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

NeuroPace Trading Down 0.4%

Shares of NPCE stock opened at $14.50 on Tuesday. The stock has a market cap of $483.00 million, a price-to-earnings ratio of -19.08 and a beta of 1.85. The company has a quick ratio of 3.94, a current ratio of 4.86 and a debt-to-equity ratio of 3.17. NeuroPace has a fifty-two week low of $7.56 and a fifty-two week high of $18.98. The firm’s 50 day moving average price is $16.10 and its two-hundred day moving average price is $12.68.

NeuroPace Company Profile

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.